Unlike everyday supplements stocked in every health store, CJC-1295 reaches researchers through a global research peptide market that Berga residents navigate through international suppliers. This concentration of supply in online vendors is a genuine benefit for researchers — top vendors distinguish themselves through rigorous testing in ways no local retailer can match. The key verification criteria for CJC-1295 are HPLC purity ≥98%, molecular identity verified through mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-matched Certificate of Analysis. The sections below cover what Berga researchers need to know about purchasing, testing, and working with CJC-1295 for research purposes.
CJC-1295: What the Research Shows
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Berga researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
How to Evaluate CJC-1295 Vendors
The first step for any Berga researcher sourcing CJC-1295 is identifying 2-3 vendors with documented positive community reputations — commercial rankings reflect SEO budgets rather than product quality. A COA for CJC-1295 should include: HPLC purity percentage with the actual chromatogram data, mass spectrometry data establishing the correct molecular weight, endotoxin test results, and a residual solvent panel — all batch-matched. Community reputation in research forums is a useful additional signal to COA verification — vendors with consistently positive reports over 12+ months have built their reputation on real product performance. The lyophilised (freeze-dried) form of CJC-1295 is much more stable than liquid pre-made solutions — lyophilised powder retains potency for years in frozen storage, while liquid preparations lose activity within weeks.
Order CJC-1295 — ships to Berga
COA-verified · International tracking · Research grade
CJC-1295 operates outside approved pharmaceutical regulation — researchers should understand that the known safety profile is based on academic studies rather than pharmaceutical approval data. Lyophilised CJC-1295 should be stored frozen (−20°C) immediately upon receipt; do not freeze and thaw reconstituted CJC-1295 multiple times by dividing into single-dose aliquots before freezing. The most significant preventable safety hazard in CJC-1295 research is bacterial endotoxin from low-quality material — a confirmed endotoxin test result in the lot-matched COA is the direct mitigation for this hazard. Researchers using CJC-1295 alongside other research compounds should examine published studies for potential interaction data before running stacked compound experiments.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
